Australia's most trusted
source of pharma news
Posted 30 June 2025 PM
All strengths of Mounjaro vials have officially been exhausted after Eli Lilly decided to discontinue the presentation in 2024 and swap to the KwikPen, a multidose delivery option of the pegged blockbuster.
Mounjaro KwikPen is available on private script for the treatment of adults with insufficiently controlled type 2 diabetes as an adjunct to diet and exercise as monotherapy when metformin is not tolerated, or contradicted, or in addition to other glycaemic control medications.
Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.